{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:01:20Z","timestamp":1768435280881,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T00:00:00Z","timestamp":1377561600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s13304-013-0229-9","type":"journal-article","created":{"date-parts":[[2013,8,26]],"date-time":"2013-08-26T17:20:46Z","timestamp":1377537646000},"page":"109-113","source":"Crossref","is-referenced-by-count":8,"title":["The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse"],"prefix":"10.1007","volume":"66","author":[{"given":"E.","family":"Saladino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fleres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Irato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Famulari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Macr\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,27]]},"reference":[{"issue":"2 Suppl","key":"229_CR1","first-page":"517","volume":"71","author":"R Yancik","year":"1993","unstructured":"Yancik R (1993) EOC: age contrast in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71(2 Suppl):517\u2013523","journal-title":"Cancer"},{"key":"229_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskin WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV EOC. N Engl J Med 334:1\u20136","journal-title":"N Engl J Med"},{"key":"229_CR3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1200\/JCO.2003.02.054","volume":"21","author":"RF Ozolos","year":"2003","unstructured":"Ozolos RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:194\u2013200","journal-title":"J Clin Oncol"},{"key":"229_CR4","first-page":"57","volume":"11","author":"RF Ozolos","year":"1988","unstructured":"Ozolos RF, Young RC (1988) Epithelial ovarian cancer. Curr Probl Cancer 11:57\u2013122","journal-title":"Curr Probl Cancer"},{"key":"229_CR5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/j.seminoncol.2008.12.002","volume":"36","author":"MM Leitao Jr","year":"2009","unstructured":"Leitao MM Jr, Chi DS (2009) Surgical management of recurrent ovarian cancer. Semin Oncol 36:106\u2013111","journal-title":"Semin Oncol"},{"key":"229_CR6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34\u201343","journal-title":"N Engl J Med"},{"key":"229_CR7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jso.21083","volume":"98","author":"CW Helm","year":"2008","unstructured":"Helm CW, Bristow RE, Kusamura S, Baratti D, Deraco M (2008) Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol 98:283\u2013290","journal-title":"J Surg Oncol"},{"key":"229_CR8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1471-0528.2011.03207.x","volume":"119","author":"M Deraco","year":"2012","unstructured":"Deraco M, Virz\u00ec S, Raspagliesi F et al (2012) Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. BJOG 119:800\u2013809","journal-title":"BJOG"},{"key":"229_CR9","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","volume":"374","author":"BT Hennessy","year":"2009","unstructured":"Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374:1371\u20131382","journal-title":"Lancet"},{"key":"229_CR10","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","volume":"106","author":"DS Chi","year":"2006","unstructured":"Chi DS, McCaughty K, Diaz JP et al (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933\u20131939","journal-title":"Cancer"},{"key":"229_CR11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3802\/jgo.2009.20.2.101","volume":"20","author":"J Bae","year":"2009","unstructured":"Bae J, Lim MC, Choi JH et al (2009) Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol 20:101\u2013106","journal-title":"J Gynecol Oncol"},{"key":"229_CR12","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter P, du Bois A, Hahmann M et al (2006) The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702\u20131710","journal-title":"Ann Surg Oncol"},{"key":"229_CR13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","volume":"16","author":"P Harter","year":"2009","unstructured":"Harter P, Hahmann M, Lueck HJ et al (2009) Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 16:1324\u20131330","journal-title":"Ann Surg Oncol"},{"key":"229_CR14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ejso.2010.03.005","volume":"36","author":"D Baratti","year":"2010","unstructured":"Baratti D, Scivales A, Balestra MR et al (2010) Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol 36:463\u2013469","journal-title":"Eur J Surg Oncol"},{"key":"229_CR15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1634\/theoncologist.2008-0275","volume":"14","author":"CW Helm","year":"2009","unstructured":"Helm CW (2009) The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 14:683\u2013694","journal-title":"Oncologist"},{"key":"229_CR16","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Arstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248\u20131259","journal-title":"J Clin Oncol"},{"key":"229_CR17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","volume":"114","author":"DS Chi","year":"2009","unstructured":"Chi DS, Eisenhauer EL, Zivanovic O et al (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114:26\u201331","journal-title":"Gynecol Oncol"},{"key":"229_CR18","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950\u20131955","journal-title":"N Engl J Med"},{"key":"229_CR19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynaecologic oncology group, southwestern oncology group, and eastern cooperative oncology group. J Clin Oncol 19:1001\u20131007","journal-title":"J Clin Oncol"},{"key":"229_CR20","first-page":"1","volume":"62","author":"RI Dedrick","year":"1978","unstructured":"Dedrick RI, Myers CE, Bungay PM et al (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1\u201311","journal-title":"Cancer Treat Rep"},{"key":"229_CR21","first-page":"CD005340","volume":"1","author":"K Jaaback","year":"2006","unstructured":"Jaaback K, Jhonson N (2006) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 1:CD005340","journal-title":"Cochrane Database Syst Rev"},{"key":"229_CR22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jnci\/djp151","volume":"101","author":"K Rowan","year":"2009","unstructured":"Rowan K (2009) Intraperitoneal therapy for ovarian cancer: why has it not become standard? J Natl Cancer Inst 101:775\u2013777","journal-title":"J Natl Cancer Inst"},{"key":"229_CR23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejso.2010.11.004","volume":"37","author":"M Deraco","year":"2011","unstructured":"Deraco M, Baratti D, Laterza B et al (2011) Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer: review of literature data. Eur J Surg Oncol 37:4\u20139","journal-title":"Eur J Surg Oncol"},{"key":"229_CR24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1586\/14737140.1.1.142","volume":"1","author":"M Markman","year":"2001","unstructured":"Markman M (2001) Intraperitoneal chemotherapy in the management of malignant disease. Expert Rev Anticancer Ther 1:142\u2013148","journal-title":"Expert Rev Anticancer Ther"},{"key":"229_CR25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4251\/wjgo.v3.i12.169","volume":"3","author":"A Macr\u00ec","year":"2011","unstructured":"Macr\u00ec A, Fortugno A, Saladino E (2011) Rationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia. World J Gastrointest Oncol 3:169\u2013174","journal-title":"World J Gastrointest Oncol"},{"key":"229_CR26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-006-9182-x","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Black D, Savady R, Sugarbaker PH (2007) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomixoma peritonei. Ann Surg Oncol 14:484\u2013492","journal-title":"Ann Surg Oncol"},{"key":"229_CR27","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1200\/JCO.2006.07.1142","volume":"24","author":"TD Yan","year":"2006","unstructured":"Yan TD, Black D, Savady R, Sugarbaker PH (2006) Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 24:4011\u20134019","journal-title":"J Clin Oncol"},{"key":"229_CR28","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237\u20136242","journal-title":"J Clin Oncol"},{"key":"229_CR29","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/(SICI)1097-0142(19970301)79:5<884::AID-CNCR3>3.0.CO;2-C","volume":"79","author":"S Fujimoto","year":"1997","unstructured":"Fujimoto S, Takahashi M, Mutou T et al (1997) Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 79:884\u2013891","journal-title":"Cancer"},{"key":"229_CR30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1525-1438.2006.00751.x","volume":"17","author":"CW Helm","year":"2007","unstructured":"Helm CW, Toler CR, Martin RS III et al (2007) Surgical cytoreduction and intraperitoneal heated chemotherapy (IPHC) for endometrial carcinoma recurrent within the peritoneal cavity. Int J Gynecol Cancer 17:204\u2013209","journal-title":"Int J Gynecol Cancer"},{"key":"229_CR31","first-page":"101","volume":"42","author":"CT Griffiths","year":"1975","unstructured":"Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101\u2013104","journal-title":"Natl Cancer Inst Monogr"},{"key":"229_CR32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","volume":"26","author":"WE Winter 3rd","year":"2008","unstructured":"Winter WE 3rd, Maxwell GL, Tian C et al (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 26:83\u201389","journal-title":"J Clin Oncol"},{"key":"229_CR33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1006\/gyno.2001.6312","volume":"82","author":"SM Eisenkop","year":"2001","unstructured":"Eisenkop SM, Spirtos NM (2001) What are the current surgical objectives, strategies, and technical capabilities of gynaecologic oncologist treating advanced epithelial ovarian cancer? Gynecol Oncol 82:489\u2013497","journal-title":"Gynecol Oncol"},{"key":"229_CR34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2004.09.018","volume":"95","author":"AR Munkarah","year":"2004","unstructured":"Munkarah AR, Coleman RL (2004) Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 95:273\u2013280","journal-title":"Gynecol Oncol"},{"key":"229_CR35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00001622-200209000-00008","volume":"14","author":"E Salom","year":"2002","unstructured":"Salom E, Almeida Z, Mirhashemi R (2002) Management of recurrent ovarian cancer: evidence-based decision. Curr Opin Oncol 14:519\u2013527","journal-title":"Curr Opin Oncol"},{"key":"229_CR36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.23553","volume":"113","author":"A Giorgio Di","year":"2008","unstructured":"Di Giorgio A, Naticchioni E, Biacchi D et al (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113:315\u2013325","journal-title":"Cancer"},{"key":"229_CR37","first-page":"3019","volume":"23","author":"E Bree de","year":"2003","unstructured":"de Bree E, Romanos J, Michalakis J et al (2003) Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 23:3019\u20133027","journal-title":"Anticancer Res"},{"key":"229_CR38","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1055\/s-2003-44484","volume":"125","author":"K Chatzigeorgiou","year":"2003","unstructured":"Chatzigeorgiou K, Economou S, ChrysaWs G et al (2003) Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). Z Gyn\u00e4kol 125:424\u2013429","journal-title":"Z Gyn\u00e4kol"},{"key":"229_CR39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jso.20597","volume":"94","author":"S Rufian","year":"2006","unstructured":"Rufian S, Munoz-Casares FC, Briceno J et al (2006) Radical surgery\u2014peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 94:316\u2013324","journal-title":"J Surg Oncol"},{"key":"229_CR40","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00268-007-9146-8","volume":"31","author":"E Cotte","year":"2007","unstructured":"Cotte E, Glehen O, Mohamed F et al (2007) Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 31:1813\u20131820","journal-title":"World J Surg"},{"key":"229_CR41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2006.10.051","volume":"105","author":"CW Helm","year":"2007","unstructured":"Helm CW, Randall-Whitis L, Martin RS III et al (2007) Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 105:90\u201396","journal-title":"Gynecol Oncol"},{"key":"229_CR42","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ejso.2009.03.004","volume":"35","author":"MJ Pavlov","year":"2009","unstructured":"Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM (2009) Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer\u201412-year single center experience. Eur J Surg Oncol 35:1186\u20131191","journal-title":"Eur J Surg Oncol"},{"key":"229_CR43","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1245\/s10434-012-2510-4","volume":"19","author":"N Bakrin","year":"2012","unstructured":"Bakrin N, Cotte E, Golfier F, et al (2012) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter prospective study of 246 patients. Ann Surg Oncol 19:4052\u20134058","journal-title":"Ann Surg Oncol"},{"key":"229_CR44","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.03.004","volume":"113","author":"A Fagotti","year":"2009","unstructured":"Fagotti A, Paris I, Grimolizzi F et al (2009) Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol 113:335\u2013340","journal-title":"Gynecol Oncol"},{"key":"229_CR45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jso.21732","volume":"103","author":"JS Frenel","year":"2011","unstructured":"Frenel JS, Leux C, Pouplin L et al (2011) Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients. J Surg Oncol 103:10\u201316","journal-title":"J Surg Oncol"},{"key":"229_CR46","first-page":"74","volume":"16","author":"J Spiliotis","year":"2011","unstructured":"Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A (2011) The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J BUON 16:74\u201379","journal-title":"J BUON"},{"key":"229_CR47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/030089160108700302","volume":"87","author":"M Deraco","year":"2001","unstructured":"Deraco M, Rossi CR, Pennacchioli E et al (2001) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 87:120\u2013126","journal-title":"Tumori"},{"key":"229_CR48","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00268-004-7461-x","volume":"28","author":"C Zanon","year":"2004","unstructured":"Zanon C, Clara R, Chiappino I et al (2004) Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 28:1040\u20131045","journal-title":"World J Surg"},{"key":"229_CR49","first-page":"1329","volume":"22","author":"G Panteix","year":"2002","unstructured":"Panteix G, Beaujard A, Garbit F et al (2002) Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res 22:1329\u20131336","journal-title":"Anticancer Res"},{"key":"229_CR50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/jso.20243","volume":"90","author":"TW Riechman","year":"2005","unstructured":"Riechman TW, Cracchiolo B, Sama J et al (2005) Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol 90:51\u201356","journal-title":"J Surg Oncol"},{"key":"229_CR51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ejso.2006.03.011","volume":"32","author":"F Raspagliesi","year":"2006","unstructured":"Raspagliesi F, Kusamura S, Campos Torres JC et al (2006) Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advance\/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol 32:671\u2013675","journal-title":"Eur J Surg Oncol"},{"key":"229_CR52","first-page":"413","volume":"4","author":"DL Chan","year":"2012","unstructured":"Chan DL, Morris DL, Rao A, Chua TC (2012) Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res 4:413\u2013422","journal-title":"Cancer Manag Res"},{"key":"229_CR53","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/BF02557372","volume":"9","author":"OA Stuart","year":"2002","unstructured":"Stuart OA, Stephens AD, Welch L et al (2002) Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mytomicin C. Ann Surg Oncol 9:186\u2013191","journal-title":"Ann Surg Oncol"},{"key":"229_CR54","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ejso.2006.03.019","volume":"32","author":"L Gonzalez-Bayon","year":"2006","unstructured":"Gonzalez-Bayon L, Gonzalez-Moreno S, Ortega-Perez G (2006) Safety consideration for operating room personnel during hyperthermic intraoperative intraperitoneal chemotherapy perfusion. Eur J Surg Oncol 32:619\u2013624","journal-title":"Eur J Surg Oncol"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-013-0229-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13304-013-0229-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-013-0229-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T22:51:18Z","timestamp":1563749478000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13304-013-0229-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,27]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["229"],"URL":"https:\/\/doi.org\/10.1007\/s13304-013-0229-9","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,27]]}}}